Tekmira Pharmaceuticals Corporation's Lipid Nanoparticle (LNP) Technology Highlighted in Two Peer-Reviewed Scientific Publications

VANCOUVER, British Columbia, Aug. 30, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced the publication of two articles in peer-reviewed scientific journals – the Journal of Infectious Diseases and New England Journal of Medicine – that highlight results enabled by Tekmira's lipid nanoparticle (LNP) technology.

Help employers find you! Check out all the jobs and post your resume.